All In Biotech

Drug Trial Radar · NCT05371080

A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults

A Phase 3b, Open-label, Multi-country, Multi-centre, Long-term Follow-up Study of ZOSTER-049 (Follow-up of ZOSTER-006/022 Studies) to Assess the Prophylactic Efficacy, Safety and Persistence of Immune Response of a Herpes Zoster Subunit Vaccine and Assessment of Persistence of Immune Response and Safety of 1 or 2 Additional Doses Administered in ZOSTER-049 in 2 Subgroups of Older Adults

Last checked: Nov 20, 2026Latest source record: Jan 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 3,038 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

3,038

Planned (sponsor's estimate)

Start

Aug 10, 2022

Primary completion

Aug 23, 2027

Study completion Aug 23, 2027

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
May 12, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the current ZOSTER-101 long-term follow-up (LTFU) study of ZOSTER-049 (NCT02723773) study, an extension of ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) primary studies, is to assess the long-term vaccine efficacy (VE) against Herpes Zoster (HZ) (approximately 11-15 years post primary vaccination in ZOSTER-006/022 studies), persistence of immunogenicity and safety of GSK's Herpes Zoster subunit (HZ/su) vaccine in older adults. The persistence of immunogenicity and safety of 1 or 2 additional doses (0, 2-month schedule) of HZ/su vaccine administered to a small group of participants in ZOSTER-049 study (approximately 5 years after the initial vaccination in ZOSTER-006/022 studies) will also be assessed.

Conditions

  • Herpes Zoster

Interventions

  • HZ/su vaccineBiological

    No study intervention is administered in this extension study. Participants received the HZ/su vaccine administered in the ZOSTER-049 (NCT02723773), ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) primary studies. In order to assess the persistence of immune responses, participants provide blood samples at Day 1 and yearly from Month 12 until Month 48 in the current ZOSTER-101 study, according to their study group assignment. In case of a suspected HZ case diagnosis in any of the participants, clinical specimens from HZ lesions (3 replicate samples, collected on the same day, per participant) are collected to confirm the diagnosis of HZ by Polymerase Chain Reaction (PCR)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants in LTFU and Control groups with confirmed HZ casesTime frame: During the total duration of ZOSTER-101 study (Day 1 through Month 48)

Locations

107 sites in 18 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Elkridge, Maryland

  • GSK Investigational Site

    Charlotte, North Carolina

  • GSK Investigational Site

    Hickory, North Carolina

  • GSK Investigational Site

    Pittsburgh, Pennsylvania

  • GSK Investigational Site

    Bristol, Tennessee

  • GSK Investigational Site

    San Antonio, Texas

  • GSK Investigational Site

    Salt Lake City, Utah

  • GSK Investigational Site

    Warrawong, New South Wales, Australia

  • GSK Investigational Site

    Westmead, New South Wales, Australia

  • GSK Investigational Site

    Geelong, Victoria, Australia

  • GSK Investigational Site

    São Paulo, Brazil

  • GSK Investigational Site

    São Paulo, Brazil

  • GSK Investigational Site

    Belo Horizonte, Minas Gerais, Brazil

  • GSK Investigational Site

    Curitiba, Paraná, Brazil

  • GSK Investigational Site

    Vancouver, British Columbia, Canada

  • GSK Investigational Site

    Victoria, British Columbia, Canada

  • GSK Investigational Site

    Halifax, Nova Scotia, Canada

  • GSK Investigational Site

    Truro, Nova Scotia, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Mirabel, Quebec, Canada

  • GSK Investigational Site

    Québec, Quebec, Canada

  • GSK Investigational Site

    Québec, Quebec, Canada

  • GSK Investigational Site

    Sherbrooke, Quebec, Canada

  • GSK Investigational Site

    Brno, Czechia

  • GSK Investigational Site

    České Budějovice, Czechia

  • GSK Investigational Site

    Hradec Králové, Czechia

  • GSK Investigational Site

    Tallinn, Estonia

  • GSK Investigational Site

    Tartu, Estonia

  • GSK Investigational Site

    Espoo, Finland

  • GSK Investigational Site

    Helsinki, Finland

  • GSK Investigational Site

    Helsinki, Finland

  • GSK Investigational Site

    Jarvenpaa, Finland

  • GSK Investigational Site

    Kokkola, Finland

  • GSK Investigational Site

    Oulu, Finland

  • GSK Investigational Site

    Pori, Finland

  • GSK Investigational Site

    Seinäjoki, Finland

  • GSK Investigational Site

    Tampere, Finland

  • GSK Investigational Site

    Turku, Finland

Showing 40 of 107 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.